- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.06. | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 20 million | 2 | Cision News | ||
| 22.06. | Curasight A/S announces its intention to carry out a directed issue of shares | 1 | Cision News | ||
| 08.06. | Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma) | 385 | PR Newswire | COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial... ► Artikel lesen | |
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| 28.05. | CURASIGHT: Interim report Q1 2026 | 2 | Cision News | ||
| 26.04. | CURASIGHT: Major Shareholding Notification - share transfer and ownership restructuring - related party transaction | 2 | Cision News | ||
| 25.03. | Resolutions of the Annual General Meeting 2026 of Curasight A/S | 2 | Cision News | ||
| 10.03. | CURASIGHT: Notice of Annual General Meeting 2026 | 1 | Cision News | ||
| 06.03. | Curasight reduces convertible debt as Fenja Capital converts and enters into a block trade | 1 | Cision News | ||
| 17.02. | Curasight to present at TD Cowen's 46th Annual Health Care Conference in Boston | 307 | PR Newswire | COPENHAGEN, Denmark, Feb. 17, 2026 /PRNewswire/ -- Curasight A/S (CPH: CURAS) a clinical-stage radiopharmaceutical company pioneering first-in-class uPAR-targeted radioligand platform therapies... ► Artikel lesen | |
| 09.02. | CURASIGHT: Major Shareholding Notification | 4 | Cision News | ||
| 12.01. | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 507 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 383 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 892 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 947 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 396 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 26.08.25 | Curasight announces acceptance of clinical trial application (CTA) for phase 1 trial with uTREAT in brain cancer patients | 340 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREAT belonging to Curasight's treatment platform.Initiation of the study marks a key... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ERASCA | 19,020 | -10,54 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 27,740 | -0,14 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,020 | -8,76 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| QIAGEN | 36,165 | -1,28 % | Märkte am Morgen: Öl, Applied Materials, Meta, Commerzbank, Telekom, Salzgitter, Südzucker, Qiagen | Die Bullen haben sich am deutschen Aktienmarkt zurückgemeldet. Der DAX legte gestern trotz einer kurzzeitigen Schwächephase zu. Am Ende lag er 0,89 Prozent höher bei 25.118 Punkten.An der Vortagen hatte... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,640 | -8,63 % | JPMorgan startet Coverage für Tango Therapeutics mit "Overweight" | ||
| APOGEE THERAPEUTICS | 134,08 | -0,14 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,380 | -7,98 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 307,83 | -3,26 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| TAYSHA GENE THERAPIES | 5,970 | -3,55 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,940 | -3,51 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| NURIX THERAPEUTICS | 23,070 | -3,27 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3 billion, including $700 million upfront payment Co-development, co-commercialization collaboration... ► Artikel lesen | |
| IMMUNOME | 22,200 | -3,14 % | Immunome Stock Up 32% in a Month: Here's What You Should Know | ||
| CG ONCOLOGY | 69,54 | -4,74 % | CG Oncology Inc.: CG Oncology Reports Positive First Results from CORE-008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients | - High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat... ► Artikel lesen | |
| VERA THERAPEUTICS | 39,130 | -7,93 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,755 | -8,73 % | Summit Therapeutics sells ridinilazole to Biossil for $500k |
CURASIGHT A/S gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-1,59 %) liegt der Kurs bei 2,470 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.